Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA

Objectives To develop an assay for the determination of ZAG in human serum, and to investigate its clinical relevance as a marker of metabolic syndrome. Design and methods A new sandwich ELISA was introduced and clinically tested. Results ZAG serum level did not differentiate healthy subjects (27.4 ± 8.3 mg/L; N = 132) from patients with metabolic syndrome (24.9 ± 8.1; N = 92). ZAG correlated with glucose, creatinine and uric acid. Conclusion The immunoassay offers a new research tool for glucose metabolism.